Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data
MENLO PARK, Calif. — September 23, 2026 Oruka Therapeutics announced positive Week 28 data from the ongoing EVERLAST-A Phase...
PASI 100
Advertisement
Alumis Advances Envudeucitinib With 54% PASI 100 Response
SOUTH SAN FRANCISCO, California, August 10, 2026 Alumis Inc. announced topline long-term results from the ongoing Phase 3 ONWARD3...
DKSH and BridgeBio Partner to Expand ATTR-CM Treatment Access
SINGAPORE, June 11, 2026 DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at...
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Advertisement
